What is the Share Price of Jagsonpal Pharmaceuticals Ltd?
- Answer Field
-
The share price of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 224.96 and for BSE is ₹ 225.2.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, JAGSONPAL PHARMACEUTICALS share price is currently at ₹ 224.96, which is down by ₹ -2.50 from its previous closing. Today, the stock has fluctuated between ₹ 222.05 and ₹ 232.84. Over the past year, JAGSONPAL PHARMACEUTICALS has achieved a return of 55.55 %. In the last month alone, the return has been 3.64 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 74.03 |
Operating Expense | 60.86 |
Net Profit | 31.99 |
Net Profit Margin (%) | 43.21 |
Earnings Per Share (EPS) | 4.74 |
EBITDA | 41.34 |
Effective Tax Rate (%) | 17.27 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
GLAXOSMITHKLINE PHARMA LT | 2959.45 | 58.70 | 29.97 | 50134.87 | 1924.30 / 3147.45 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.
The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.
The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future.
It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.
In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.
The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.
On June 27, 2022, Infinity Holdings, an India-focused investment group acquired control over the Company consequent to acquisition of 43.73% of equity capital and became Promoters of the Company. The Company identified several products as part of new launches such as Indocap Gel, Lycored Plus, MemUp, Queezy ER to enhance healthcare professionals' confidence and improve patient outcomes in 2023-24. It acquired the India and Bhutan business of Yash Pharma in May, 2024.
The share price of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 224.96 and for BSE is ₹ 225.2.
The market cap of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 14,93.40 Cr. and for BSE is ₹ 0.0 Cr. as of now.
The 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 328.04 and ₹ 110.00 and for BSE is ₹ 328.02 and ₹ 109.42.
You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 55.55%.
Jagsonpal Pharmaceuticals Ltd share price is for NSE ₹ 224.96 & for BSE ₹ 225.2 as on Apr 30 2025 03:30 PM.
The market cap of Jagsonpal Pharmaceuticals Ltd for NSE ₹ 14,93.40 & for BSE ₹ 0.0 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Jagsonpal Pharmaceuticals Ltd share is 28.58.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Jagsonpal Pharmaceuticals Ltd share is 29.69.
You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.
To buy Jagsonpal Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Jagsonpal Pharmaceuticals Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found